Lea Eslava-Kim, PharmD

Positive findings from the APPROACH study, which reached its primary end point, and showed the efficacy of volanesorsen therapy for patients with famimlial chylomicronemia syndrome (FCS).

A positive phase 3 study showed that patients treated with LJPC-501 were likely to achieve pre-specified blood pressure targets vs placebo.

A new drug application for warafin potassium has been submitted to the FDA.